Cerity Partners LLC Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Cerity Partners LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 16.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 249,219 shares of the medical research company's stock after selling 47,540 shares during the quarter. Cerity Partners LLC owned approximately 0.14% of IQVIA worth $49,456,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pine Valley Investments Ltd Liability Co lifted its position in IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after acquiring an additional 50 shares during the last quarter. Howard Capital Management Inc. lifted its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after purchasing an additional 54 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the period. Cypress Wealth Services LLC grew its stake in IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after buying an additional 57 shares during the last quarter. Finally, Harbor Investment Advisory LLC increased its position in IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after buying an additional 58 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

NYSE IQV traded up $2.18 during trading hours on Friday, reaching $145.40. The company's stock had a trading volume of 2,601,630 shares, compared to its average volume of 1,384,213. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company's 50-day moving average is $182.32 and its two-hundred day moving average is $199.38. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The stock has a market cap of $25.64 billion, a PE ratio of 19.39, a PEG ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. Barclays restated an "equal weight" rating and set a $170.00 target price (down from $235.00) on shares of IQVIA in a research report on Thursday. Stifel Nicolaus dropped their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.